Search the Newsreel

EuroEyes Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend

Deutsche Euroshop-Aktie gesucht: Gewinn im ersten Halbjahr gestiegen

EuroGroup Laminations S.p.A.: dati finanziari previsioni stime e aspettative EGLA | MarketScreener Italia

ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and Promising Biomarker Signals in Phase 1b Trial

ProMIS Neurosciences (PMN) reported strong Q2 2026 earnings call highlights, emphasizing zero ARIA-E cases and promising biomarker signals in its Phase 1b PRECISE-AD trial. The company maintains a strong cash position of $53.4 million, funding operations through 2027, and is advancing its pipeline candidates …

(CLPT) Price Dynamics and Execution-Aware Positioning

This article from Stock Traders Daily analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) focusing on its price dynamics and execution-aware positioning. It identifies a strong near-term sentiment despite broader weak alignment, highlighting an exceptional 142.5:1 risk-reward setup targeting a 44.2% gain. The analysis provides specific …

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)

Two healthcare companies, Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT), recently received bullish ratings from analysts. Myles Minter from William Blair reiterated a Buy rating for Alto Neuroscience, with a consensus price target of $35.71. Jonna Kim from TD Cowen also reiterated a Buy …

NeuroOne Medical Technologies Corporation Q3 2026 Earnings Call Summary

XBP Global Holdings earnings missed by $0.01, revenue fell short of estimates

XBP Global Holdings (NASDAQ: XBP) reported Q2 EPS of $-1.420, missing analyst estimates by $0.01, and revenue of $191.31M, falling short of the consensus estimate of $200.1M. Despite the miss, the company's stock price has risen 35.850% in the last three months, though it …

CCEP Downgraded by UBS -- Price Target Lowered to $107.00

UBS analyst Sanjeet Auija downgraded Coca-Cola Europacific Partners PLC (CCEP) from Buy to Neutral, lowering the price target to $107.00 from $109.00 due to a cautious outlook. Despite a strong GF Score of 85/100, CCEP is considered 5.9% overvalued by GuruFocus, though its P/E …

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants

Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

EuroHoldings Posts Record Q2 2026 Earnings and Advances Tanker Fleet Expansion

Q2 Earnings Highlights: Euronet Worldwide (NASDAQ:EEFT) Vs The Rest Of The Diversified Financial Services Stocks

Q2 Earnings Highlights: Euronet Worldwide (NASDAQ:EEFT) Vs The Rest Of The Diversified Financial Services Stocks The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how …

XBP Global Expects $65M-$75M in Annual AI Efficiencies

XBP Global (NASDAQ: XBP) reported Q2 2026 revenue of $191.3 million, a 14.0% year-over-year decline on a pro forma basis, and a net loss of $16.7 million, despite an 8.4% increase in Normalized EBITDA to $21.9 million. The company significantly raised its expected annualized …

ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D

ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences announced its Q2 2026 financial results, ending the quarter with $53.4 million in cash, expected to fund operations through 2027. The company also provided positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial for PMN310 in early …

ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary

ProMIS Neurosciences Inc. reported a net loss of $(11.73)M for Q2 2026, with a diluted loss per share of $(1.28), an increase in net loss compared to Q2 2025 but an improvement in diluted EPS. The company generated no product revenue. Key highlights include …

Alto Neuroscience stock hits all-time high at 32.74 USD

Alto Neuroscience Inc. (ANRO) stock has reached an all-time high of $32.74, marking a 906.09% increase over the past year. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently announced a stock offering to raise $100 million, received a reiterated …

Why Euro Manganese Inc stock is plummeting today

Wedbush Adjusts Price Target on Alto Neuroscience to $26 From $24, Keeps Neutral Rating

Wedbush has increased its price target for Alto Neuroscience from $24 to $26, while maintaining a Neutral rating on the stock. The article also briefly mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and a quarterly loss …

Euroseas Ltd. (ESEA) Stock Price, News, Quote & History

Euroseas Q2 adjusted EPS rises 11.9% to $4.70, beats estimates

Euroseas Q2 Earnings Call Highlights

Key Points Interested in Euroseas Ltd.? Here are five stocks we like better. Strong second-quarter results: Euroseas reported $33.2 million in net income and $40.1 million in adjusted EBITDA, while its average time-charter-equivalent rate increased to $30,306 per vessel per day despite operating one …

Deutsche EuroShop mit guter operativer Entwicklung im ersten Halbjahr 2026 und bestätigter Prognose

Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat

Alto Neuroscience (NYSE:ANRO) shares rose 8% after reporting a quarterly loss of $0.65 per share, surpassing the consensus estimate of a $0.73 loss. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $36.62, and institutional investors like Commodore Capital and …

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Earnings call transcript: Euroseas tops Q2 2026 profit estimates as shares edge higher

Euroseas Ltd. reported strong second-quarter 2026 results, surpassing profit estimates with adjusted earnings of $4.70 per share, significantly above the $4.09 forecast. The company's performance was driven by robust charter rates, near-perfect fleet utilization, and reduced financing costs, despite a slight revenue miss. Euroseas …

Euroseas Ltd. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ESEA) 2026-08-13

Coca-Cola Europacific Partners plc : UBS is niet langer positief gestemd

Eurofins CDMO Alphora Expands Kilolab and High Potency Development and Manufacturing Capabilities

MISSISSAUGA, Ontario, August 13, 2026--(BUSINESS WIRE)--Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities in Mississauga. The expanded laboratories are designed to support the growing demand for enhanced flexibility as part of process development, scale-up, and …

UBS downgrades Coca-Cola Europacific Partners despite Q2 sales, volume beat

UBS downgraded Coca-Cola Europacific Partners (CCEP) to "neutral" from "buy" and trimmed its price target due to limited upside after a 19% rally year-to-date and re-rating to a 20% premium. This occurred despite CCEP beating Q2 organic revenue and volume growth estimates. While management …

Earnings call transcript: NeuroOne Medical posts Q3 2026 revenue growth as shares fall

NeuroOne Medical Technologies reported a 16% year-over-year increase in Q3 2026 product revenue, reaching $2.0 million, driven by stronger sales of its OneRF brain ablation products and a 43% jump in orders. Despite revenue growth and improved gross margins, the company's net loss widened …

UBS Downgrades Coca-Cola Europacific Partners to Neutral From Buy, Adjusts PT to $107 From $109

UBS has downgraded Coca-Cola Europacific Partners (CCEP) from a "Buy" rating to "Neutral." The firm also adjusted its price target for CCEP, lowering it from $109 to $107. This change reflects an updated outlook on the company's stock performance.